Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1762655rdf:typepubmed:Citationlld:pubmed
pubmed-article:1762655lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1762655lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:1762655lifeskim:mentionsumls-concept:C0206726lld:lifeskim
pubmed-article:1762655lifeskim:mentionsumls-concept:C1536403lld:lifeskim
pubmed-article:1762655lifeskim:mentionsumls-concept:C0021747lld:lifeskim
pubmed-article:1762655lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1762655lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:1762655pubmed:issue11lld:pubmed
pubmed-article:1762655pubmed:dateCreated1992-2-7lld:pubmed
pubmed-article:1762655pubmed:abstractTextWe compared the regulatory effects of interferon (IFN)-beta and IFN-gamma on the susceptibility of a human gliosarcoma line GI-1 to the attack of autologous cloned tumor-specific cytotoxic T-lymphocytes (CTL) and lymphokine-activated killer (LAK) cells. Preincubation of GI-1 cells with IFN-gamma caused augmented susceptibility to the cytotoxic attack of two autologous CTL clones, whereas IFN-beta exhibited no such marked effect. On the other hand, preincubation with either IFN-beta or IFN-gamma made the GI-1 cells resistant to the attack of autologous LAK cells. Both IFNs augmented the surface expression of HLA class-I molecules on GI-1 cells. A monoclonal anti-HLA class-I antibody blocked the cytolysis by one CTL clone, but not by the other one. These results suggest that IFN-gamma exerts some different effect (s) from that of IFN-beta on the target GI-1 cells in their susceptibility to the CTL-mediated cytolysis, and that recognition mechanisms of target cells by the CTL are different from those by LAK cells. This draws our attention to IFN administration in adoptive immunotherapy against brain tumors using CTLs and LAK cells.lld:pubmed
pubmed-article:1762655pubmed:languagejpnlld:pubmed
pubmed-article:1762655pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1762655pubmed:citationSubsetIMlld:pubmed
pubmed-article:1762655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1762655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1762655pubmed:statusMEDLINElld:pubmed
pubmed-article:1762655pubmed:monthNovlld:pubmed
pubmed-article:1762655pubmed:issn0301-2603lld:pubmed
pubmed-article:1762655pubmed:authorpubmed-author:IwasakiKKlld:pubmed
pubmed-article:1762655pubmed:authorpubmed-author:KikuchiHHlld:pubmed
pubmed-article:1762655pubmed:authorpubmed-author:AokiTTlld:pubmed
pubmed-article:1762655pubmed:authorpubmed-author:OdaYYlld:pubmed
pubmed-article:1762655pubmed:authorpubmed-author:OhyamaKKlld:pubmed
pubmed-article:1762655pubmed:authorpubmed-author:OotsukaSSlld:pubmed
pubmed-article:1762655pubmed:authorpubmed-author:MiyatakeSSlld:pubmed
pubmed-article:1762655pubmed:authorpubmed-author:KondouSSlld:pubmed
pubmed-article:1762655pubmed:issnTypePrintlld:pubmed
pubmed-article:1762655pubmed:volume19lld:pubmed
pubmed-article:1762655pubmed:ownerNLMlld:pubmed
pubmed-article:1762655pubmed:authorsCompleteYlld:pubmed
pubmed-article:1762655pubmed:pagination1053-9lld:pubmed
pubmed-article:1762655pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:1762655pubmed:meshHeadingpubmed-meshheading:1762655-...lld:pubmed
pubmed-article:1762655pubmed:meshHeadingpubmed-meshheading:1762655-...lld:pubmed
pubmed-article:1762655pubmed:meshHeadingpubmed-meshheading:1762655-...lld:pubmed
pubmed-article:1762655pubmed:meshHeadingpubmed-meshheading:1762655-...lld:pubmed
pubmed-article:1762655pubmed:meshHeadingpubmed-meshheading:1762655-...lld:pubmed
pubmed-article:1762655pubmed:meshHeadingpubmed-meshheading:1762655-...lld:pubmed
pubmed-article:1762655pubmed:meshHeadingpubmed-meshheading:1762655-...lld:pubmed
pubmed-article:1762655pubmed:meshHeadingpubmed-meshheading:1762655-...lld:pubmed
pubmed-article:1762655pubmed:year1991lld:pubmed
pubmed-article:1762655pubmed:articleTitle[Immunomodulatory effects of interferons on target human gliosarcoma cells in the tumor-specific CTL- and LAK-mediated cytolysis].lld:pubmed
pubmed-article:1762655pubmed:affiliationDepartment of Neurosurgery, Faculty of Medicine, Kyoto University.lld:pubmed
pubmed-article:1762655pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1762655pubmed:publicationTypeEnglish Abstractlld:pubmed